Axsome's phase III PARADIGM study evaluating solriamfetol in major depressive disorder fails to show a statistically significant change in the primary endpoint.

It was a busy week in the biotech sector, marked by significant regulatory and pipeline updates. Among these, shares of ...

Axsome Therapeutics (AXSM) stock falls as its depression drug solriamfetol fails in a Phase 3 trial for those with daytime ...

Axsome Therapeutics AXSM announced top-line data from the phase III PARADIGM study, which evaluated solriamfetol for the treatment of major depressive disorder (MDD) with and without severe ...

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report)‘s stock had its “buy” rating reissued by analysts at Needham & Company ...

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a ...

Mizuho Securities analyst Graig Suvannavejh maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report) today and set a price ...

Axsome Therapeutics said on Tuesday it will narrow the focus of a late-stage study of its depression drug after an initial ...

After Axsome Therapeutics (AXSM) yesterday reported negative results from its Phase 3 major depressive disorder trial evaluating Sunosi as a ...

KLP Kapitalforvaltning AS acquired a new stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities ...

CNS specialist Axsome Therapeutics has announced results from the PARADIGM Phase III proof-of-concept trial of solriamfetol ...